Morpholine

Morpholine

SCHEMBL546850

C1COCCN1.CCCS(=O)(=O)O

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 2/20 0.36
LMNA P02545 3/20 0.33
ALDH1A1 P00352 1/20 0.33
APP P05067 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.30
GABRA1 P14867 1/20 0.30
GABRG2 P18507 1/20 0.30
NFKB1 P19838 1/20 0.30
GABRB3 P28472 1/20 0.30
GABRA5 P31644 1/20 0.30
GABRA3 P34903 1/20 0.30
GABRA2 P47869 1/20 0.30
GABRA6 Q16445 1/20 0.30
PTGS1 P23219 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morpholine SCHEMBL29233239 0.98 MEN1 (0.41) MEN1KMT2AKDM4EGAACYP2C9
Morpholine SCHEMBL27977283 0.98 MEN1 (0.41) MEN1KMT2AKDM4EGAACYP2C9
Morpholine SCHEMBL3318867 0.90 MEN1 (0.41) MEN1KMT2AKDM4EGAACYP2C9
Morpholine SCHEMBL668275 0.87 MEN1 (0.50) MEN1KMT2AKDM4EGAACYP2C9
Morpholine SCHEMBL3330271 0.87 MEN1 (0.50) MEN1KMT2AKDM4EGAACYP2C9
Aziridine SCHEMBL29141899 0.87 TSHR (0.43) MEN1KMT2AGAATSHRLMNA
Morpholine SCHEMBL6941937 0.85 MEN1 (0.48) MEN1KMT2AKDM4EGAACYP2C9
Morpholine SCHEMBL28118007 0.85 MEN1 (0.48) MEN1KMT2AKDM4EGAACYP2C9
Morpholine SCHEMBL28395409 0.85 MEN1 (0.48) MEN1KMT2AKDM4EGAACYP2C9
Morpholine SCHEMBL1509059 0.85 MEN1 (0.48) MEN1KMT2AKDM4EGAACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 999 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145664-A1 PHARMACEUTICAL COMPOSITIONS FOR IMAGING, DIAGNOSIS AND TREATMENT OF CANCER JUBILANT DRAXIMAGE INC (CA) 2025-05-08 US claimed
US-20250108136-A1 METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES THERAGNOSTICS LIMITED (GB) 2025-04-03 US claimed
EP-4489858-A1 EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS Harrow IP, LLC (US) 2025-01-15 EP claimed
CN-111936117-B Covalent treatment of keratin-containing materials 生活实验公司 2025-01-07 CN claimed
EP-4401797-A1 PHARMACEUTICAL COMPOSITIONS FOR IMAGING, DIAGNOSIS AND TREATMENT OF CANCER Jubilant Draximage, Inc. (CA) 2024-07-24 EP claimed
US-12036293-B2 Methods and kits for preparing radionuclide complexes THERAGNOSTICS LIMITED (GB) 2024-07-16 US claimed
CN-117925735-A Application of azo reductase in catalyzing reduction of p-benzoquinone to generate hydroquinone 中国科学院武汉病毒研究所 2024-04-26 CN claimed
WO-2023172240-A1 EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS HARROW IP, LLC (US) 2023-09-14 WO claimed
CN-115962983-A Preparation method of exosome transmission electron microscope sample 上海前瞻创新研究院有限公司 2023-04-14 CN claimed
WO-2023037337-A1 PHARMACEUTICAL COMPOSITIONS FOR IMAGING, DIAGNOSIS AND TREATMENT OF CANCER Jubilant Radiopharma (CA) 2023-03-16 WO claimed
US-6180238-B1 PARTICULARLY SUITABLE FOR USE IN INK JET PRINTING PROCESSES. XEROX CORPORATION 2001-01-30 US claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0673784-B1 Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds XEROX CORP (US) 1999-10-27 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5534374-A Migration imaging members XEROX CORPORATION (US) 1996-07-09 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
EP-0673784-A2 Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds XEROX CORPORATION (US) 1995-09-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250108136-A1 METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXES FOLH1, GAA, GMNN MEN1 82/4885KMT2A 3116/4885KDM4E 3679/4885
US-12036293-B2 Methods and kits for preparing radionuclide complexes FOLH1, GAA, GMNN MEN1 82/4885KMT2A 3116/4885KDM4E 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.